ArriVent BioPharma, Inc. Common Stock

AVBPNASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
30.35 USD
↘ 2.74 (8.28%)AT CLOSE (11:59 AM EDT)
30.38
↗ 0.03 (0.08%)
POST MARKET (AS OF 04:21 PM EDT)
Post Market
AS OF 04:21 PM EDT
30.38
↗ 0.03 (0.08%)
🔴Market: CLOSED
Open?$32.80
High?$32.98
Low?$30.30
Prev. Close?$33.09
Volume?634.9K
Avg. Volume?519.1K
VWAP?$30.82
Rel. Volume?1.22x
Bid / Ask
Bid?$29.15 × 100
Ask?$32.47 × 100
Spread?$3.32
Midpoint?$30.81
Valuation & Ratios
Market Cap?1.4B
Shares Out?46.6M
Float?21.7M
Float %?52.5%
P/E Ratio?N/A
P/B Ratio?4.36
EPS?-$3.12
Dividend?0.00%
Ex-Dividend?N/A

AVBP is currently priced at $30.35. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. AVBP is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
Themes
Healthcare - Oncology›Targeted Therapy & Precision Oncology
Employees
77
Market Cap
1.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.arrivent.com
Listed
2024-01-26
Address
18 CAMPUS BLVD.
NEWTOWN SQUARE, PA 19073-3269
Phone: 240-780-6356
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
77
Short Sent.?
10
Piotroski F-Score?0/9Weak
Altman Z-Score?31.34Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?33.67%Squeeze Risk
Short Interest?7.3M
Days to Cover?22.6
Free Float21.7M
Avg Daily Volume323.7K
Settlement Date2026-05-15
Financial Health
Current Ratio?13.95Strong
Quick Ratio?13.95Strong
Cash Ratio?2.48Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
41
4.36FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-8.4CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-44.8%WEAK▾
ROA?
S&P
3
-41.6%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$1.4B
Fundamentals ratios updated end of day
MarketsMoversWatchlist